Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BGB-16673

Contact Research Centre

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting

Registered drugNo placebo

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Infliximab

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Registered drugNo placebo

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Breast cancer

Recruiting

Registered drug

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Inavolisib

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Recruiting

InvestigationalNo placebo

Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:Danicopan

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Registered drugNo placebo

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo

Germany

Participants:65+ years
Substances:Busulfan

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

Registered drugNo placebo

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acalabrutinib

Contact Research Centre

Medulloblastoma

Recruiting

Registered drugNo placebo

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin

Contact Research Centre

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting

Registered drugNo placebo

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Bortezomib

Contact Research Centre

Medulloblastoma

Recruiting

Registered drugNo placebo

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you – page 2

85 trials match your criteria

Triple negative breast cancer

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Non-small cell lung cancer

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Chronic lymphocytic leukaemia+1

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Diffuse large B-cell lymphoma

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Breast cancer

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Paroxysmal nocturnal haemoglobinuria

Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

Diffuse large B-cell lymphoma

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Chronic lymphocytic leukaemia

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Medulloblastoma

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Medulloblastoma

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.